Mosquera D A, Gibson S P, Goldman M D
Department of Surgery, East Birmingham Hospital, UK.
Nephrol Dial Transplant. 1992;7(11):1111-5.
The results of a 2-year prospective study of primary and secondary vascular access surgery for haemodialysis have been compared with a retrospective study of central venous access via a flexible silicone catheter (Permcath). Cumulative patency for 61 primary fistulae in 57 patients was 64.8% at 1 year and 57.7% at 2 years. The patency of 55 secondary procedures in 43 patients was 48.1% at 1 and 2 years. Cumulative survival of 64 Permcaths inserted into 51 patients was 74% at 1 year and 43% at 2 years. Surgical complications included explorations for bleeding (2), haematomas (4), swollen arms (4), and inadequately dilated veins (4). Permcath complications included explorations for bleeding (3) and a temporary recurrent laryngeal nerve palsy (1). Exit site infection and septicaemia rates were 4.95 and 3.36 per 1000 catheter days respectively, but 20.6% of septicaemic episodes occurred in a patient who refused catheter removal. For haemodialysis, the Permcath is comparable with secondary vascular access. The Permcath may have a primary access role in patients with limited life expectancy.
一项针对血液透析的原发性和继发性血管通路手术的2年前瞻性研究结果,已与一项通过软性硅胶导管(Permcath)进行中心静脉通路的回顾性研究进行了比较。57例患者的61条原发性动静脉内瘘1年时的累积通畅率为64.8%,2年时为57.7%。43例患者的55次继发性手术在1年和2年时的通畅率为48.1%。51例患者植入的64根Permcath导管1年时的累积生存率为74%,2年时为43%。手术并发症包括因出血进行的探查(2例)、血肿(4例)、手臂肿胀(4例)以及静脉扩张不足(4例)。Permcath导管相关并发症包括因出血进行的探查(3例)和1例暂时性喉返神经麻痹。出口部位感染率和败血症发生率分别为每1000导管日4.95例和3.36例,但20.6%的败血症发作发生在拒绝拔除导管的患者中。对于血液透析,Permcath导管与继发性血管通路相当。Permcath导管在预期寿命有限的患者中可能具有原发性血管通路的作用。